Figure 4.
![Comparison of rwOS after applying IPTW between patients with high- and non–high-risk CLL/SLL using an alternative definition of high risk [presence of del(17p) or unmutated IGHV only], and in Medicare subgroups.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/15/10.1182_bloodadvances.2024015417/1/blooda_adv-2024-015417-gr4.jpeg?Expires=1756616905&Signature=CXfOm5L5aMWBBCjNyMtp4k0~lKV5S502sP2TCj~cHG8bftqgMd2JQs~3JcEqzR338CitdEw0Vq-D6QLlyRiHt3LQfWndvpSMGoN2U8krD1XDKoS9hDwvziyD0zwWNaY0VVjgI3QTVbBW3Y-LYG1vars7C2-DQIWeL4l7Z3dw~dYY-Rte0K7jnlijlw9fFW~dthAXJsEh7vV6TNwgCOeI2rbUjlMzbNOhNI3U-Cboa3QrKQf-9tXNA8rEwyMeEjaMRRLrNY34OuOwRg8hhVr0p1QHxFRhjbjNwj9eERCXXboBP2wC4Np47oJQJIwmXIuKSd0pLwYBCQrTunuM6LK~3Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Comparison of rwOS after applying IPTW between patients with high- and non–high-risk CLL/SLL using an alternative definition of high risk [presence of del(17p) or unmutated IGHV only], and in Medicare subgroups.
Comparison of rwOS after applying IPTW between patients with high- and non–high-risk CLL/SLL using an alternative definition of high risk [presence of del(17p) or unmutated IGHV only], and in Medicare subgroups.
